January 2023

Dr. Josep Comín, co-author of two publications in Nature Medicine and JACC on a new drug against heart failure

Leave a Comment / Sin categorizar / By

The international group of scientists who have discovered the benefits of dapagliflozin in the treatment of heart failure, including Dr. Josep Comín, head of the IDIBELL BIO-Heart Research Group on Cardiovascular Diseases and the Cardiology Service of the Hospital de Bellvitge, has published new disaggregated results of this research in the leading scientific journals Nature Medicine and the Journal of the American College of Cardiology (JACC).

Two brain regions size could predict the psychological behavioral therapy effectiveness in children with OCD

Leave a Comment / Neuroscience Area, Neuroscience Program, Psychiatry and Mental Health  / By

A study by the Bellvitge Biomedical Research Institute (IDIBELL), the Bellvitge University Hospital, the University of Barcelona, and CIBERSAM observes that children with increased volume of two prefrontal cortex structures respond better to cognitive behavioral therapy.

Allogeneic transplantation from a matched registry donor may have better results than that from a less well-matched relative

Leave a Comment / Cancer, Hematopoyetic and lymphoid tumors , Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell / By

A study led by the Catalan Institute of Oncology and IDIBELL, published in the scientific journal ‘Transplantation and Cellular Therapy’, concludes that, whenever possible, it is better for the patient to receive a transplant from a highly compatible registry donor than from a haploidentical donor with a family relationship, but less compatible.

The Niemann-Pick Foundation finances a clinical trial of a drug to stop the cognitive deterioration of the disease

Leave a Comment / Neurologic Diseases and Neurogenetics , Neuroscience Area, Neuroscience Program / By

Today the Niemann-Pick Spain Foundation came to deliver the check for 71,056.25 euros that will fully finance a pilot study to determine the efficacy and safety of the drug Efavirenz to alleviate the cognitive deterioration of patients with this minority disease of genetic origin and for which there is currently no treatment. The event was …

The Niemann-Pick Foundation finances a clinical trial of a drug to stop the cognitive deterioration of the disease Read More »

A study that identifies for the first time more than 100 new genetic factors linked to colorectal cancer

Leave a Comment / Cancer, Colorectal Cancer, Molecular Mechanisms and Experimental Therapy in Oncology Program - Oncobell / By

This is the largest study on the genetics of colorectal cancer risk. The study, carried out by a global consortium, with the participation of IDIBELL and the Catalan Institute of Oncology, opens new strategies for treatment and chemoprevention.

Scroll to Top